Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OvaCyst is a veterinary injectable formulation of the gonadotropin-releasing hormone (GnRH) analog gonadorelin diacetate tetrahydrate, containing 50 mcg/mL gonadorelin, used in cattle for reproductive management. By mimicking endogenous hypothalamic GnRH, gonadorelin stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby inducing ovulation and luteinization of follicular ovarian cysts and enabling synchronization of estrous cycles when used in timed artificial insemination (FTAI) protocols with prostaglandin analogs such as cloprostenol sodium.[1][7] It is supplied as a sterile intramuscular or intravenous solution for use by licensed veterinarians in dairy and beef cows for treatment of cystic ovaries and for estrus synchronization programs.[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OvaCyst.